These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12719201)

  • 1. Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus.
    Safford M; Eaton L; Hawley G; Brimacombe M; Rajan M; Li H; Pogach L
    Arch Intern Med; 2003 Apr; 163(8):922-8. PubMed ID: 12719201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial and ethnic disparities in the control of cardiovascular disease risk factors in Southwest American veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study.
    Wendel CS; Shah JH; Duckworth WC; Hoffman RM; Mohler MJ; Murata GH
    BMC Health Serv Res; 2006 May; 6():58. PubMed ID: 16716235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
    Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
    Boytsov S; Logunova N; Khomitskaya Y;
    Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians.
    Vijan S; Hayward RA;
    Ann Intern Med; 2004 Apr; 140(8):650-8. PubMed ID: 15096337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
    Hanefeld M; Traylor L; Gao L; Landgraf W
    Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus.
    Emanuele N; Azad N; Abraira C; Henderson W; Colwell J; Levin S; Nuttall F; Comstock J; Sawin C; Silbert C; Marcovina S; Lee HS
    Arch Intern Med; 1998 Dec 7-21; 158(22):2485-90. PubMed ID: 9855387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of type 2 diabetes mellitus: a novel approach for addressing glycemic and lipid control with colesevelam HCl.
    Wright WL
    Adv Nurse Pract; 2009 Nov; 17(11):suppl 1-16. PubMed ID: 20014684
    [No Abstract]   [Full Text] [Related]  

  • 10. Heart matters: Gender and racial differences cardiovascular disease risk factor control among veterans.
    Goldstein KM; Melnyk SD; Zullig LL; Stechuchak KM; Oddone E; Bastian LA; Rakley S; Olsen MK; Bosworth HB
    Womens Health Issues; 2014; 24(5):477-83. PubMed ID: 25213741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
    Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: data from the Adult Diabetes Control and Management.
    Sazlina SG; Mastura I; Ahmad Z; Cheong AT; Adam BM; Jamaiyah H; Lee PY; Syed-Alwi SA; Chew BH; Sriwahyu T
    Geriatr Gerontol Int; 2014 Jan; 14(1):130-7. PubMed ID: 23581598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
    Leiter LA; Cariou B; Müller-Wieland D; Colhoun HM; Del Prato S; Tinahones FJ; Ray KK; Bujas-Bobanovic M; Domenger C; Mandel J; Samuel R; Henry RR
    Diabetes Obes Metab; 2017 Dec; 19(12):1781-1792. PubMed ID: 28905478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus.
    Krempf M; Berthezène F; Wemeau JL; Moinade S; Desriac I; Amelineau E; Passa P
    Diabetes Metab; 1997 Apr; 23(2):131-6. PubMed ID: 9137901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial).
    Meyers CD; McCarren M; Wong ND; Abraira C; Duckworth WC; Kashyap ML;
    Am J Cardiol; 2006 Jul; 98(1):63-5. PubMed ID: 16784922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint effect of race/ethnicity or location of residence and sex on low density lipoprotein-cholesterol among veterans with type 2 diabetes: a 10-year retrospective cohort study.
    Weeda ER; Bishu KG; Ward R; Axon RN; Taber DJ; Gebregziabher M
    BMC Cardiovasc Disord; 2020 Oct; 20(1):449. PubMed ID: 33059602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease.
    Goldstein KM; Stechuchak KM; Zullig LL; Oddone EZ; Olsen MK; McCant FA; Bastian LA; Batch BC; Bosworth HB
    J Womens Health (Larchmt); 2017 Jul; 26(7):806-814. PubMed ID: 28192012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.